Skip to main content

Molecular mechanism of protein-protein and membrane-protein interactions in cellular processes.

RYC2018-023837-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Development of pharmacological tools to study the kv4.3 channelosome in atrial fibrillation

  • Viedma, Carmen
  • Sandin, P.
  • Bonache de Marcos, María Ángeles
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Resumen del trabajo presentado en el XX National Meeting of the Spanish Society of Medicinal Chemistry, celebrado en Santiago de Compostela (España) del 19 al 22 de junio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions, such as smooth muscle contraction or secretion of hormones. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3 and its role in atrial fibrillation (AF). KV4.3 channel is expressed in smooth muscle, heart and brain. Its activation generates outward currents operating at subthreshold membrane potentials as recorded from myocardial cells (ITO, transient outward current). KV4.3 plays a key role in AF, the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] To reproduce the ITO currents, KV4.3 channels need to assemble with other subunits, forming channelosome. KChIPs (Potassium Channel Interacting Proteins), which belong to the calcium binding protein superfamily, forms the KV4.3 channelosome, along with other proteins.[3] To study the complex interaction of KV4.3 channelosome and the development of modulators, the interplay of different techniques is central to advance knowledge. In this regard, the development of novel KChIPs modulators and fluorescent biosensors constitutes invaluable pharmacological tools to unravel the KV4 channelosome and its role in AF.[3] In this communication, we will describe preliminary results towards the identification of new pharmacological tools to study the KChIPs/KV4 interaction., This work was supported by the projects: PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 funded by MCIN/ AEI /10.13039/501100011033; and the projects PIE202180E073 and 2019AEP148 funded by CSIC. C. Viedma Barba holds the grant PRE2020-093542 and M. Valencia holds the grant PRE2020-093950, both funded by MCIN/AEI/10.13039/501100011033. A. Pérez-Lara holds the grant RYC2018-023837-I funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Study of kv4.3 channelosome: novel kchip2 ligands as pharmacological tools

  • Martinez-Salas, P.
  • Viedma, Carmen
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Daniel-Mozo, Miguel
  • Albert, Armando
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
Trabajo presentado en el VIII Symposia of medicinal chemistry young researchers, celebrado en Barcelona (España) el 22 de julio de 2022., Ion channels are macromolecular complexes present in the plasma membrane and in intracellular organelles of the cells, where they play important functions. The dysfunction of these channels results in several disorders named channelopathies, which represent a challenge for study and treatment.[1] We are focused on voltage-gated potassium channels, specifically on KV4.3. Within the heart, KV4.3 channels generate the transient outward potassium current (ITO). However, ITO characteristics are only observed when KV4.3 assembles with accessory subunits as KChIP2 and DPP6. KV4.3 channelosome play a key role in atrial fibrillation (AF), the most common cardiac arrhythmia, with an estimated prevalence in the general population of 1.5–2%. However, current antiarrhythmic drugs for AF prevention have limited efficacy and considerable potential for adverse effects.[2] KChIP2 (Potassium Channel Interacting Protein 2) belongs to the calcium binding protein superfamily. It is the KChIP member predominantly expressed in heart and a key regulator of cardiac action potential duration. Novel KChIP2 ligands could be a useful pharmacological tool to understand the role of KV4.3 channelosome in AF and it could help to discover new treatments for AF. [3] In this communication, we will describe a multidisciplinary approach that, starting with a structure-based virtual screening, followed by an iterative process of synthesis/biological evaluation/docking studies, has led to the identification of new KChIP2 ligands., PID2019-104366RB-C21, PID2019-104366RB-C22, PID2020-114256RB-I00 and PID2020-119805RB-I00 grants funded by MCIN/AEI/10.13039/501100011033; and PIE202180E073 and 2019AEP148 funded by CSIC. C.V.B. holds PRE2020-093542 FPI grant funded by MCIN/AEI/10.13039/501100011033. PGS was recipient of an FPU grant (FPU17/02731). AB-B holds BES-2017-080184 FPI grant and A.P-L.holds RYC2018-023837-I grant both funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of a new selective ligand for targeting neuronal KV4.3/KChIP3 over cardiac KV4.3/KChIP2 channels

  • Socuellamos, Paula G.
  • Viedma-Barba, Carmen
  • de Benito-Bueno, Angela
  • Bonache de Marcos, María Ángeles
  • Ropero, Maria
  • Diez, Sara
  • Elizalde, Pablo
  • Marín-Olivero, Irene
  • Redondo-Moya, Maria
  • Naranjo, Jose Ramon
  • Gonzalez-Vera, Juan A.
  • Orte, Angel
  • Perez-Lara, Angel
  • Martín-Martínez, Mercedes
  • Valenzuela, Carmen
  • Gutiérrez-Rodríguez, Marta
The present study aimed to discover novel KChIP ligands as pharmacological tools for modulating the KV4.3/KChIP channels. A multidisciplinary approach, combining medicinal chemistry and electrophysiology studies, led to the successfully identification of a novel KV4.3/KChIP modulator (IQM-22110). Its design was guided by the previous knowledge of the (phenylacetamido)benzoic acid moiety as suitable scaffold, along with virtual screening of a focused chemical library that suggested improved KChIP3 binding upon incorporation of an additional aromatic ring. IQM-22110 was selected for synthesis and identified as a potent KChIP3 ligand. Its electrophysiological effects on KV4.3/KChIP3 currents indicate that IQM-22110 binds to a high affinity site in KV4.3/KChIP3 channels that it is not present in KV4.3/KChIP2 or KV4.3. To the best of our knowledge, here we describe the first KChIP3 ligand that selectively modulates KV4.3/KChIP3 versus KV4.3/KChIP2 and KV4.3 channels at nanomolar concentration. Since KChIP2 is predominantly expressed in cardiac tissue, this selectivity may enable the development of KV4.3/KChIP3-targeted therapeutics with reduced risk of cardiac side effects. Computational and site-directed mutagenesis studies allowed the identification of IQM-22110's binding site on KChIP3. Knowledge gained from structural and functional studies with this novel KChIP3 ligand could establish the basis for drug discovery programs fostering treatments for diseases in which KV4.3/KChIPs channels are involved., This work has been funded by grants: PID2022-137214OB-C21 (to CV) and PID2022-137214OB-C22 (to MG-R) funded by MCIN/AEI/h ttps://doi.org/10.13039/501100011033 and by “ERDF A way of mak ing Europe”; PID2023-148243OB-I00 AEI/https://doi.org/10.13039/ 501100011033 (to AO); Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to C.V.); CSIC grants 202580E109 (to MMM and MG-R) and 2023AEP049 (to CV); P. G. Socuéllamos was funded by FPU17/02731 granted by Spanish Minister of Science and Innovation. C. Viedma-Barba holds a FPI Predoctoral contracts subsidized by Spanish Minister of Science and Innovation (PRE2020-093542) granted by MCIN/AEI/https://doi.org/10.13039/501100011033 and “ESF Invest ing in your future”. A. de Benito-Bueno holds a FPI grant BES- 2017–080184. M. Redondo holds a FPI Contract subsidized by Spanish Minister of Science and Innovation (PREP2022-000706). A.P.-L. ac knowledges funding by a Ramon y Cajal grant (RYC2018-023837-I) and Max Planck Society through the funding of a Max Planck Partner Group on “Regulation of the SNARE zippering by complexins and synapto tagmins” at the University of Granada. We thank Centro de Supercomputaciónn de Galicia (CESGA) and Centro Técnico de Informática, CTI-CSIC for computer time at FinisTerrae III and DRAGO, respectively., Peer reviewed